Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 66 of 66 entries
View as:

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05162755 Org: User:
Start: 10/15/21 End: 06/19/25 Due: 06/19/26

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT06465953 Org: User:
Start: 12/03/24 End: 12/01/28 Due: 12/01/29

Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)

Phase: N/A Priority: Normal
NCT ID: NCT02375685 Org: User:
Start: 08/31/14 End: 11/30/15 Due: 11/30/16

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02848443 Org: User:
Start: 05/31/16 End: 04/09/20 Due: 04/09/21

The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT00143507 Org: User:
Start: 12/31/04 End: 02/29/08 Due: 02/28/09

Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies

Phase: N/A Priority: Normal
NCT ID: NCT03274882 Org: User:
Start: 03/03/17 End: 12/03/18 Due: 12/03/19

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02074839 Org: User:
Start: 03/01/14 End: 03/31/26 Due: 03/31/27

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03411161 Org: User:
Start: 01/04/18 End: 06/08/20 Due: 06/08/21

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02920541 Org: User:
Start: 01/31/15 End: 05/24/18 Due: 05/24/19

Safety of Single Intravenous Administration of S95010 in Human Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03494712 Org: User:
Start: 02/21/18 End: 04/10/19 Due: 04/10/20

Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT05638334 Org: User:
Start: 11/21/22 End: 06/14/24 Due: 06/14/25

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02053636 Org: User:
Start: 12/31/13 End: 04/04/17 Due: 04/04/18

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder

Phase: N/A Priority: Normal
NCT ID: NCT03715166 Org: User:
Start: 09/24/18 End: 09/13/21 Due: 09/13/22

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)

Phase: N/A Priority: Normal
NCT ID: NCT02989857 Org: User:
Start: 02/20/17 End: 05/17/21 Due: 05/17/22

A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02743221 Org: User:
Start: 04/29/16 End: 09/01/20 Due: 09/01/21

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

Phase: N/A Priority: Normal
NCT ID: NCT03715153 Org: User:
Start: 10/04/18 End: 10/26/21 Due: 10/26/22